Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Reviews of Physiology, Biochemistry and Pharmacology|January 28, 2005
Pharmacological properties of cerium compoundsM A Jakupec, P Unfried, B K KepplerReviews of Physiology, Biochemistry and Pharmacology|February 28, 2003
Tumour-inhibiting platinum complexes--state of the art and future perspectivesM A Jakupec, M S Galanski, B K KepplerMetal-Based Drugs|October 1, 2009
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and InvasionA Bergamo, A Masi, M A Jakupec, et al.Current Pharmaceutical Design|May 26, 2023
Corrigendum to: Recent Developments in the Field of Tumor-Inhibiting Metal ComplexesM S Galanski, V B Arion, M A Jakupec, et al.Current Pharmaceutical Design|October 8, 2003
Recent Developments in the Field of Tumor-Inhibiting Metal ComplexesM S Galanski, V B Arion, M A Jakupec, et al.Dalton Transactions (Cambridge, England : 2003)|November 12, 2014
Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potentialP-S Kuhn, V Pichler, A Roller, et al.Journal of Cancer Research and Clinical Oncology|October 27, 2004
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cellsS Kapitza, M Pongratz, M A Jakupec, et al.Biochemical Pharmacology|April 21, 2007
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24)P Heffeter, M A Jakupec, W Körner, et al.The Journal of Pharmacology and Experimental Therapeutics|August 28, 2004
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)P Heffeter, M Pongratz, E Steiner, et al.Current Cancer Drug Targets|June 11, 2009
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772)P Heffeter, A Popovic-Bijelic, P Saiko, et al.Pageof 2